Form 4 for SYRE Spyre Therapeutics, Inc.
Accepted 2026-07-02 21:33:02 ET · period of report 2026-07-01 · accession 0001636282-26-000087 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-07-02 21:33 | 2026-07-01 | SYRE | Sloan Sheldon | Chief Medical Off | M - OptEx | $27.46 | +8,334 | 8,334 | New | +$228.9K |
| DMT | 2026-07-02 21:33 | 2026-07-01 | SYRE | Sloan Sheldon | Chief Medical Off | S - Sale+OE | $87.70 | -8,334 | 0 | -100% | -$730.9K |
| DT | 2026-07-02 21:33 | 2026-07-01 | SYRE | Sloan Sheldon | Chief Medical Off | M - OptEx | $0.00 | -8,334 | 305.0K | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-01 | M | A | 8,334 | $27.46 | 8,334 | D | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. |
| 2 | Common | Common Stock | 2026-07-01 | S | D | 6,500 | $87.52 | 1,834 | D | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. (F2) The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.03 to $87.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. |
| 3 | Common | Common Stock | 2026-07-01 | S | D | 1,834 | $88.34 | 0 | D | — | — | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. (F3) The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.03 to $88.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| 4 | Derivative | Stock Option (Right to Buy) | 2026-07-01 | M | D | 8,334 | $0.00 | 305,000 | D | $27.46 · — to 2034-10-01 | 8,334 Common Stock | (F1) This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on June 20, 2025. (F4) This option represents the right to purchase 400,000 shares of the Issuer's common stock, one quarter of which vested and became exercisable on October 1, 2025, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. |